A novel process for the preparation of a compound of the formula (II), which is useful as intermediate compound for the preparation of thiazolidinedione derivatives, such as rosiglitazone, pioglitazone, troglitazone and ciglitazone, is disclosed. The novel process comprising reacting a compound of the formula (III) with a compound of the formula (IV) in a mixture of a non- polar water immiscible organic solvent and water (two phase system) with an alkali metal hydroxide or an alkali metal carbon...

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin lovastatin simvastatin fluvastatin rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone pioglitazone englitazone BRL-49653 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]- ethoxy}benzyl)thiazolidine-24-dione 5-{4-(5-methoxy-3-methylimidazo[54-b]pyridin-2-yl- methoxy)benzyl}thiazolidine-24-dione or its hydrochloride 5-[4-(6-methoxy-1-methylbenzimidazol-2-yl- methoxy)benzyl]t...

Insulin sensitizers especially thiazolidinedione compounds such as troglitazone are useful for the treatment and prevention of pancreatitis.lt;/ SDOABgt;

This invention provides a process for reducing an exocyclic double bond at the 5-position of a thiazolidinedione moiety of a thiazolidinedione precursor comprising the steps of: a) preparing a solution or suspension of the thiazolidinedione precursor in a non-ether solvent medium with a base and b) combining the solution or suspension with a dithionite source. Preferred solvent media include aqueous NN-dimethylformamide. Sodium dithionite is a preferred dithionite source. In particular the appli...

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1 R2 R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases especially type II diabetes and other diseases as set out herein employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such ...

A method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance in humans or non-human mammals which method comprises the administration of an effective non-toxic and pharmaceutically acceptable amount of PPARy agonist such as Compound (I) or a pharmaceutically acceptable derivative thereof. Conditions associated with cardiac insulin resistance are: microvascular angina atherosclerosis and congestive heart failure. Compounds includ...

The proliferation of uterine fibroid leiomyoma cells is inhibited by certain Fibroid Cell Growth Inhibitor (FGI) agents. Pharmacological doses of FGI agents can be made high enough to not only inhibit proliferation but to cause cell death. Non-invasive or minimally invasive non-systemic delivery methods deliver the FGI agent to the target fibroid leiomyoma cell population thereby avoiding the disadvantages and side effects of surgical and systemic hormonal therapy interventions for treatment of ...

The proliferation of uterine fibroid leiomyoma cells is inhibited by certain Fibroid Cell Growth Inhibitor (FGI) agents. Pharmacological doses of FGI agents can be made high enough to not only inhibit proliferation, but to cause cell death. Non-invasive or minimally invasive, non-systemic delivery methods deliver the FGI agent to the target fibroid leiomyoma cell population, thereby avoiding the disadvantages and side effects of surgical and systemic hormonal therapy interventions for treatment ...